Optimism dominates AIDS vaccine confab
- AIDS vaccine suffers setback in US. Roberts, John // BMJ: British Medical Journal (International Edition);6/11/94, Vol. 308 Issue 6943, p1527
Reports the HIV infection of seven people involved in early trials of AIDS vaccine in the United States. Influence of gp120 fragment from the outer coat of the virus on the production of antibodies; Study on the safety of the vaccines; Details on the risk of acquiring HIV infection.
- WHO/UNAIDS HIV vaccine initiative calls for accelerated research to build on trial accomplishments. // Weekly Epidemiological Record;2/28/2003, Vol. 78 Issue 9, p62
Reveals that the World Health Organization/United Nations AIDS HIV vaccine initiative calls for accelerated research to build on trial accomplishments. Need for expansion of existing prevention efforts; Updates in companies developing AIDS/HIV vaccines.
- Prospects for live attenuated HIV. Desrosiers, Ronald C. // Nature Medicine;Sep98, Vol. 4 Issue 9, p982
Comments on the use of live attenuated HIV-1 strains as a vaccine approach for AIDS. Risks associated with the use of live vaccine strains in clinical trials involving human volunteers; Argument that advancement of life attenuated vaccines should not occur at the expense of other vaccine...
- Gender differences in HIV-1 diversity at time of infection. Michelle Long, E.; Martin, Harold L.; Kreiss, Joan K.; Rainwater, Stephanie M.J.; Lavreys, Ludo; Jackson, Denis J.; Rakwar, Joel; Mandaliya, Kishorchandra; Overbaugh, Julie // Nature Medicine;Jan2000, Vol. 6 Issue 1, p71
To develop an HIV-1 vaccine with global efficacy, it is important to identify and characterize the viruses that are transmitted, particularly to individuals living in areas of high incidence. Several studies have shown that virus from the blood of acutely infected adults was homogeneous, even...
- New AIDS vaccine offers cautious hope. Wareham, Hannah Clay // Bay Windows;10/1/2009, Vol. 27 Issue 41, p1
The article presents information on a new HIV vaccine, RV 144, which prevented new infections in 31.2 percent of the 16,000 Thai volunteers in a study.
- The magic bullet. Wells, Ken R. // Advocate;11/28/95, Issue 695, p40
Looks at the lack of funds for the development of vaccines for the prevention of HIV infection. Decision of pharmaceuticals and private investors to divert funds to the development of therapeutic approaches for the disease; Profitability of a cure for AIDS instead of a means of prevention.
- Safety and Immunogenicity of a Canarypox-Vectored HIV Type 1 Vaccine with or without gp120. Belshe, Robert B.; Stevens, Cladd; Gorse, Geoffrey J.; Buchbinder, Susan; Sheppard, Haynes; Stablein, Donald; Self, Steve; McNamara, James; Frey, Sharon; Flores, Jorge; Excler, Jean Louis; Klein, Michel; El Habib, Raphaelle; Duliege, Anne-Marie; Harro, Clayton; Corey, Lawrence; Keefer, Michael; Mulligan, Mark; Wright, Peter; Celum, Connie // Journal of Infectious Diseases;5/1/2001, Vol. 183 Issue 9, p1343
Presents a study which examined the safety and immunogenicity of a canarypox vector HIV type 1 vaccine with or without gp120 boosting. Methodology; Results; Discussion.
- AIDS Vaccines: Progress and Unmet Challenges. Bolognesi, Dani P. // Annals of Internal Medicine;1/15/91, Vol. 114 Issue 2, p161
Editorial. Focuses on the progress of the development of HIV or AIDS vaccines. Issues ignored in developing a vaccine; Models used in clinical trials; Recommendations for the design of clinical trials.
- Microbicides 2002: An Update. Johnston, Rowena // AIDS Patient Care & STDs;Sep2002, Vol. 16 Issue 9, p419
Given that an acquired immune deficiency syndrome (AIDS) vaccine is more likely to mitigate than avert human immunodeficiency virus (HIV) infection, prevention efforts are focused on the development of a microbicide to reduce the sexual transmission of HIV. In this context, a microbicide might...